Results 11 to 20 of about 153,721 (218)

Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

Pulmonary Circulation, 2021
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam, Ryan Avery, Isaac Goldberg, Courtney Makowski, Ravi Kalhan, Victoria Villaflor, Michael J. Cuttica   +6 more
doaj   +1 more source

Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer

Scientific Reports, 2023
Immune checkpoint inhibitors have significantly improved the prognosis in patients with non-small cell lung cancer, compared with cytotoxic agents.
Minehiko Inomata, Masahiro Matsumoto, Naoki Takata, Kana Hayashi, Zenta Seto, Takahiro Hirai, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe   +14 more
doaj   +1 more source

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

Experimental Hematology & Oncology, 2020
This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production ...
Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen, Tue Wenzel Kragstrup   +3 more
doaj   +1 more source

Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas

iScience, 2023
Summary: Evidence is mounting for cross-resistance between immune checkpoint and targeted kinase inhibitor therapies in cutaneous melanoma patients. Since the loss of the transcription factor, SOX10, causes tolerance to MAPK pathway inhibitors, we used ...
Timothy J. Purwin, Signe Caksa, Ahmet Sacan, Claudia Capparelli, Andrew E. Aplin   +4 more
doaj   +1 more source

Chronic immune checkpoint inhibitor pneumonitis

Journal for ImmunoTherapy of Cancer, 2020
Background Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve with 4–6 weeks
Julie R Brahmer, Patrick M Forde, Evan J Lipson, Jarushka Naidoo, Joanne Riemer, Daphne Wang, Janis M Taube, Cheng Ting Lin, Peter B Illei, Tricia R Cottrell, Lonny B Yarmus, K Ranh Voong, David Feller-Kopman, Hans Lee, Sonye K Danoff, Franco R D'Alessio, Karthik Suresh   +16 more
doaj   +1 more source

Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review

Frontiers in Oncology, 2023
Immune checkpoint inhibitors cause rare but potentially fatal neuromuscular complications, leading to a concern to use these agents in cancer patients with pre-existing autoimmune or inflammatory neuromuscular diseases.
Ge Xiong, Richard Benjamin Young, Helen Chow, Emanual Maverakis, Ricardo A. Maselli, David Paul Richman, Tianhong Li   +6 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Associated Myocarditis

JACC: Case Reports, 2020
Immune checkpoint inhibitors (ICIs) can induce immunity-related adverse events. We demonstrate the clinical use of cardiac magnetic resonance and endomyocardial biopsy in the diagnosis and subsequent monitoring of ICI-associated myocarditis, suggesting ...
Grigorios Chatzantonis, MD, Georg Evers, MD, Claudia Meier, MD, Michael Bietenbeck, PhD, Anca Florian, MD, Karin Klingel, MD, Annalen Bleckmann, MD, Ali Yilmaz, MD   +7 more
doaj   +1 more source

Bell's palsy during rechallenge of immune checkpoint inhibitor

IJU Case Reports, 2023
Introduction The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features ...
Kohji Takemura, Taro Yamanaka, Michikata Hayashida, Rika Kizawa, Takeshi Yamaguchi, Yuko Tanabe, Kazushige Sakaguchi, Koichi Suyama, Shinji Urakami, Yuji Miura   +9 more
doaj   +1 more source

Immune checkpoint inhibitor-associated sarcoidosis reaction [PDF]

Journal of Nephropathology, 2023
Immune checkpoint inhibitors (ICIs) constitute a class of drugs that stimulate the immune system to fight cancer cells. However, they can also induce immune-related adverse events (irAEs) in various organs, including the kidneys.
Parisa Keshtgar, Parisa Kaviani, Payam Peymani, Neda Kianpour, Samin Karamian   +4 more
doaj   +1 more source

Immune checkpoint inhibitor myocarditis: a systematic case study

Российский кардиологический журнал, 2020
Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors.
E. A. Kushnareva, O. M. Moiseeva
doaj   +1 more source